Signaling pathways involved in colorectal cancer progression
Zahra Koveitypour, Farnoush Panahi, Mehrdad Vakilian et al. · Cell & Bioscience · 2019 · Review
Full textCC BY
Oncology
Filters3 filters applied
Status
- Retracted
- Expression of concern
- Corrected
- No notice
- From publisher notices and Retraction Watch. Not checked means nobody has looked yet.
Year
Readable here
Study type
Licence
Xenograft and organoid model systems in cancer research
Margit Bleijs, Marc van de Wetering, Hans Clevers et al. · The EMBO Journal · 2019 · Review
Full textCC BY
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher, A. E. Stacy, G. M. Porter et al. · Journal of Experimental & Clinical Cancer Research · 2019 · Review
Full textCC BY
Resilience in Cancer Patients
Annina Seiler, Josef Jenewein · Frontiers in Psychiatry · 2019 · Review
Full textCC BY
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years
Fanny ER Vuik, Stella AV Nieuwenburg, Marc Bardou et al. · Gut · 2019
Full textCC BY
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao, Yu J. Cao · Frontiers in Immunology · 2019 · Review
Full textCC BY
Chemoresistance in Pancreatic Cancer
Siyuan Zeng, Marina Pöttler, Bin Lan et al. · International Journal of Molecular Sciences · 2019 · Review
Full textCC BY
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhongwei Zhao, Liyun Zheng, Weiqian Chen et al. · Journal of Hematology & Oncology · 2019 · Review
Full textCC BY
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu, Qihang Sun, Xiaoqian Liang et al. · Frontiers in Immunology · 2019 · Review
Full textCC BY
Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
Mercedes Segovia, Sofia Russo, Mathias Jeldres et al. · Cancer Cell · 2019
Full textCC BY
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Andrea Forschner, Florian Battke, Dirk Hadaschik et al. · Journal for ImmunoTherapy of Cancer · 2019
Full textCC BY
Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals
Wanying Guo, Xin Lu, Qipeng Liu et al. · Cancer Medicine · 2019 · Meta-analysis
Full textCC BY
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye, Zoaib Rasool · Journal of Hematology & Oncology · 2019 · Review
Full textCC BY
Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update
Noushin Lotfi, Rodolfo Thome, Nahid Rezaei et al. · Frontiers in Immunology · 2019 · Review
Full textCC BY
Corrected The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Akram Pourshams, Sadaf G Sepanlou, Kevin S Ikuta et al. · The Lancet Gastroenterology & Hepatology · 2019
Full textCC BY
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
Anqi Lin, Ting Wei, Hui Meng et al. · Molecular Cancer · 2019 · Review
Full textCC BY
Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
Zhibo Zhang, Ye Li, Xiang Yan et al. · Cancer Medicine · 2019 · Meta-analysis
Full textCC BY
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Evangeline M. Foster, Adrià Dangla-Valls, Simon Lovestone et al. · Frontiers in Neuroscience · 2019 · Review
Full textCC BY
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura et al. · Journal for ImmunoTherapy of Cancer · 2019
Full textCC BY
Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling
Heike Reeh, Nadine Rudolph, Ulrike Billing et al. · Cell Communication and Signaling · 2019
Full textCC BY